Posted on

The trendy parenting hack

Moms who microdose ‘magic’ mushrooms say the psychedelic made them better parents

 

Moms around the world are microdosing magic mushrooms to become better parents.

Natalie from Oakland, CA is one of many moms who’ve turned to microdoing to cope with postpartum depression. She was suffering so much that she was worried she’d harm her newborn, which made her suicidal.

Since microdosing 100mg of mushrooms daily for one month, she’s been able to go off antidepressants and ADHD medications. She says she feels more stable than ever and can now face motherhood with a sense of calm.

“Microdosing let me know who I really am…I’m able to parent myself and my daughter in a whole different way, because when I microdose, I know I’ve got this”, Natalie said in an interview with Insider.

Posted on

Studying the most depressed patients

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression

“This will be the broadest study of its kind.”

This morning, Braxia Scientific (BRAX) announced that it’s launching Canada’s first multiple-dose psilocybin trial for treatment resistant depression (TRD).

Most TRD studies recruit patients who have tried a maximum of five other treatment options, but this study will have no upper limit on the number of failed treatments. Braxia researchers will even include patients who’ve gone through dozens of medical trials with no success, including ketamine and electroconvulsive therapy patients.

The randomized clinical trial will also include some patients with bipolar depression or comormid disorders, which are typically excluded from psychedelic studies.

“By including everyone with more than two failed medical trials, we are increasing the degree to which the results can be applied to a larger population, making our findings much stronger”, said the trial’s principal investigator.

Posted on

300% growth?

This Psychedelics Stock Could Grow 300% In One Year

Experts predict major growth for this psychedelics stock.

Last week, the financial services firm Cantor Fitzgerald initiated coverage of Cybin Inc. (CYBN).

The stock was just $2.25 per share when the firm gave Cybin a 12-month price target of $9  – a 300% margin.

The analysts believe that Cybin’s proprietary formulation for treating depression which is in phase 2 clinical trials, has great potential for scalability. They explain that Cybin has enough capital to advance its other formulations for anxiety and alcohol use disorder through clinical trials as well.

 

Posted on

How to bond with strangers

Minnesota Psychedelic Therapy Clinic, Institute for Integrative Therapies, Begins Offering Psychedelic Therapy in a Group Setting

“We have a crisis of loneliness and isolation.” Is group psychedelic therapy the solution?

This week, the Institute for Integrative Therapies (IIT) in Minnesota began offering ketamine-assisted therapy in group settings, and will soon offer group therapy with psilocybin and MDMA too.

Group sessions can provide a powerful healing experience and a sense of connection, plus they’re much cheaper than one-on-one sessions at just $500 per person for a 3-hour experience.

Participants work with a therapist both individually and in group settings to prepare for the experience before laying on a floor mat and tripping in a room full of strangers. Each group has a focus such as depression, anxiety, PTSD, existential crises, grief, end of life distress, and LGBTQ experiences.

PDF of article

Posted on

Psilocybin will be bigger than cannabis, says a cannabis exec

Cannabis Firm Plans South Africa IPO, Magic Mushroom Expansion

South Africa’s first cannabis company is shifting to psilocybin, which shouldn’t be a surprise given its name – Cilo Cybin Pharmaceutical Ltd.

The company recently applied for a research permit to study psilocybin for depression, anxiety, and PTSD. “I really think it is going to be a lot bigger than cannabis even,” said the CEO.

He plans to take the company public on the Johannesburg and Luxembourg Stock Exchanges within the next 12 months.

PDF of article

Posted on

Finally some research on microdosing

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin 

There’s tremendous anecdotal evidence that microdosing has therapeutic benefits, yet there’s limited research on its effects. Luckily, that’s starting to change thanks to Diamond Therapeutics.

The Toronto-based company received Health Canada approval to conduct a Phase 1 human clinical trial to evaluate low doses of psilocybin in up to 80 healthy volunteers. The preclinical research suggests that low, non-hallucinogenic doses have potential therapeutic benefits.

Diamond Therapeutics is also planning to conduct a Phase 2 trial in the US and Canada to evaluate low psilocybin doses in treating anxiety and will support an investigator-led study on moderate depression as well.

PDF of article

Posted on

Psychedelics make you more open minded… obviously

Do our brains predict how we think? Psychedelics may help answer that question

It’s actually backed by science!

Research suggests that 5-HT2A serotonin receptors play an important role in a flexible thinking since they’re found in the region of the brain responsible for learning and cognition. A study conducted on rats found that when these receptors are blocked, the rats became unable to spontaneously change from one behaviour to another to earn a reward, indicating a decrease in cognitive flexibility.

Psilocybin activates the 5-HT2A serotonin receptors, as its chemical structure is quite similar to serotonin, which explains why so many users experience an increase in cognitive flexibility and a decrease in rigid thought patterns. Lack of cognitive flexibility is often associated with disorders like depression and OCD, so it makes sense that psilocybin is being used to treat these conditions!

PDF of article

Posted on

Largest psilocybin study continues to grow

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

The world’s largest psilocybin therapy study on depression is approaching completion, and it’s even bigger than expected.

Compass Pathways (CMPS) announced that it’s close to completing its phase 2b trial on treatment-resistant depression, and expects to report the findings by the end of this year. So far, 233 patients have received COMP360 psilocybin therapy, exceeding the target of 216. The company also announced its Q2 financial highlights including $316.3 million in cash and equivalents as of June 30.

PDF of article

Posted on

Prevent wrinkles ;) … and cancer

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells

Mushroom tea could be the secret to aging gracefully.

Aging, as well as several chronic diseases like cancer, arthritis, neurodegeneration, chronic depression, and cardiovascular disease, are often tied to pathological inflammation.

A new study from a South African university revealed that psilocybin mushrooms have potent anti-inflammatory properties that could help treat chronic these conditions. Researchers analyzed 4 species of psilocybin mushrooms, which were extracted in hot water, and discovered that they suppressed the body’s inflammatory response by inhibiting several inflammatory proteins.

PDF of study

Posted on

Are mushrooms the key to life on other planets?

Future Space Travel Might Require Mushrooms

If you’re looking for an out-of-this-world experience, try tripping in space.

Mycology expert Paul Stamets believes that psilocybin mushrooms can help astronauts work through the depression, loneliness, and PTSD that comes from being isolated in space. “Under carefully controlled conditions, our astronauts [being] able to take psilocybin in space and look at the universe and not feel distant and alone but feel like they’re part of this giant consciousness will give them a better frame of mind—psychologically, emotionally—to work with other astronauts and stay on mission.”

Stamets is working with NASA to explore the emerging field of astromycology –  the study of fungal biology throughout the universe. In a recent interview, he said that mushrooms can produce biodiverse environments with rich soil that may help astronauts grow food on other planets. Blocks made from reishi mushrooms even have potential to create extraterrestrial shelters because they’re great at retaining heat and are insanely strong (a hydraulic stainless steel press broke when trying to crush a reishi block). Plus, they are rich in carbon fibers, so they could possibly become solar powered batteries!